gemfibrozil has been researched along with Hyperlipoproteinemia Type III in 14 studies
Hyperlipoproteinemia Type III: An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nineteen adult patients with type III hyperlipoproteinemia (HLP) and homozygosity for apolipoprotein (apo) E2 were treated with the 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) reductase inhibitor simvastatin (20 or 40 mg per day) alone or in combination with the fibrate derivative gemfibrozil (450 mg per day) during a 30-week outpatient study." | 9.07 | The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia. ( Eichinger, M; Feussner, G; Ziegler, R, 1992) |
| "Nineteen adult patients with type III hyperlipoproteinemia (HLP) and homozygosity for apolipoprotein (apo) E2 were treated with the 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) reductase inhibitor simvastatin (20 or 40 mg per day) alone or in combination with the fibrate derivative gemfibrozil (450 mg per day) during a 30-week outpatient study." | 5.07 | The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia. ( Eichinger, M; Feussner, G; Ziegler, R, 1992) |
| "In patients with type III hyperlipoproteinemia gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is." | 2.69 | Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. ( Cenarro, A; Civeira, F; Ferrando, J; Garcia-Otín, AL; Mozas, P; Pocoví, M; Puzo, J, 1999) |
| "Familial dysbetalipoproteinemia is an inherited disorder in which both cholesterol and triglycerides are elevated in the plasma of the blood, which pre-disposes people to coronary artery disease and peripheral vascular disease." | 1.35 | Familial dysbetalipoproteinemia: a potentially fatal disorder. ( Bari, AU; Hashim, R; Hussain, M; Rahman, SB, 2008) |
| "Treatment with clofibrate and gemfibrozil both resulted in significant reductions in the plasma concentrations of total cholesterol (40% and 54%), VLDL cholesterol (59% and 79%) and total triglycerides (48% and 70%), as well as a significant increase in HDL cholesterol (9% and 7%)." | 1.29 | Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia. ( Illingworth, DR; Larsen, ML; O'Malley, JP, 1994) |
| "Gemfibrozil treatment in patients with familial dysbetalipoproteinemia resulted in a marked reduction of the concentrations of large VLDL, small VLDL, and IDL, and an increase in the levels of HDL, apo A-I, and apo A-II." | 1.29 | Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil. ( Leuven, JA; Smelt, AH; van 't Hooft, FM; van der Laarse, A; Vroom, TF; Zhao, SP, 1994) |
| "In this study, 3 patients with familial dysbetalipoproteinemia were treated with lovastatin, and kinetics for apolipoprotein B (apo B) were determined in control and drug treatment periods." | 1.27 | Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. ( East, C; Grundy, SM; Vega, GL, 1988) |
| "Tuboeruptive xanthomata, palmar xanthoma, and xanthoma striata palmare subsided with treatment." | 1.27 | Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease. ( Dodge, HT; Kostis, JB; Kuo, PT; Moreyra, AB; Wilson, AC, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (50.00) | 18.7374 |
| 1990's | 6 (42.86) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bari, AU | 1 |
| Hashim, R | 1 |
| Rahman, SB | 1 |
| Hussain, M | 1 |
| Larsen, ML | 1 |
| Illingworth, DR | 1 |
| O'Malley, JP | 1 |
| Zhao, SP | 2 |
| Smelt, AH | 2 |
| Leuven, JA | 1 |
| Vroom, TF | 1 |
| van der Laarse, A | 1 |
| van 't Hooft, FM | 1 |
| Mulder, M | 1 |
| Frants, RR | 1 |
| Havekes, LM | 1 |
| Guyton, JR | 1 |
| Civeira, F | 1 |
| Cenarro, A | 1 |
| Ferrando, J | 1 |
| Puzo, J | 1 |
| Garcia-Otín, AL | 1 |
| Mozas, P | 1 |
| Pocoví, M | 1 |
| Feussner, G | 1 |
| Eichinger, M | 1 |
| Ziegler, R | 1 |
| Vega, GL | 1 |
| East, C | 1 |
| Grundy, SM | 1 |
| Houlston, R | 1 |
| Quiney, J | 1 |
| Watts, GF | 1 |
| Lewis, B | 2 |
| Kuo, PT | 1 |
| Wilson, AC | 1 |
| Kostis, JB | 1 |
| Moreyra, AB | 1 |
| Dodge, HT | 1 |
| Weintraub, MS | 1 |
| Eisenberg, S | 1 |
| Breslow, JL | 1 |
| Gotto, AM | 1 |
| Jones, PH | 1 |
| Scott, LW | 1 |
| Schaefer, EJ | 1 |
| Levy, RI | 1 |
| Turner, PR | 1 |
| Cortese, C | 1 |
| Wootton, R | 1 |
| Marenah, C | 1 |
| Miller, NE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for gemfibrozil and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr | 1986 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylom | 1985 |
3 trials available for gemfibrozil and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
Treatment of E2E2 homozygous familial dysbetalipoproteinemic subjects with gemfibrozil does not enhance the binding of their d < 1.019 lipoprotein fraction to the low-density lipoprotein receptor.
Topics: Apolipoproteins A; Cells, Cultured; Cholesterol; Dose-Response Relationship, Drug; Female; Gemfibroz | 1993 |
Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
Topics: Adult; Apolipoproteins; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type | 1999 |
The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.
Topics: Adult; Apolipoprotein E2; Apolipoproteins E; Cholesterol; Cholesterol, LDL; Combined Modality Therap | 1992 |
9 other studies available for gemfibrozil and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
Familial dysbetalipoproteinemia: a potentially fatal disorder.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hyp | 2008 |
Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia.
Topics: Adult; Aged; Cholesterol; Clofibrate; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type III; Li | 1994 |
Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
Topics: Adult; Aged; Centrifugation, Density Gradient; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Elec | 1994 |
Treatment of type III hyperlipoproteinemia.
Topics: Apolipoproteins E; Cholesterol, LDL; Cholesterol, VLDL; Gemfibrozil; Humans; Hyperlipoproteinemia Ty | 1999 |
Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.
Topics: Adult; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Female; Gemfibrozil; Hum | 1988 |
Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia.
Topics: Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; | 1988 |
Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease.
Topics: Adult; Combined Modality Therapy; Coronary Disease; Drug Evaluation; Exercise Test; Female; Gemfibro | 1988 |
Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.
Topics: Cholestyramine Resin; Chylomicrons; Dietary Fats; Female; Gemfibrozil; Humans; Hyperlipoproteinemia | 1987 |
Plasma apolipoprotein B metabolism in familial type III dysbetalipoproteinaemia.
Topics: Adult; Aged; Apolipoproteins B; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type III; Kinetics | 1985 |